Physician profile
Ryan Owen
NPI 1275820151
$11,397.30
in general payments reported to CMS, 2019-2025
33 companies · $2,078 in 2025
The $2,078 reported for 2025 was more than what 77% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,105 · 2020: $800 · 2021: $1,793 · 2022: $1,223 · 2023: $1,966 · 2024: $2,433 · 2025: $2,078.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,097 · Education: $380.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,096.85 |
| Education | $379.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $2,013.99 | 2019-2025 | Adbry, Anzupgo |
| Novartis Pharmaceuticals Corporation | $1,469.80 | 2019-2025 | |
| Janssen Biotech, INC. | $1,324.87 | 2019-2025 | Tremfya, Stelara, Remicade |
| Abbvie INC. | $1,224.40 | 2020-2025 | |
| Regeneron Healthcare Solutions, INC. | $757.09 | 2021-2025 | Dupixent, Libtayo |
| Biofrontera INC. | $617.29 | 2021 | |
| Pfizer INC. | $565.52 | 2019-2025 | |
| Genzyme Corporation | $464.45 | 2019-2025 | |
| Incyte Corporation | $461.50 | 2022-2025 | Opzelura |
| Dermavant Sciences, INC. | $325.96 | 2022-2024 | Vtama |
| Sun Pharmaceutical Industries INC. | $311.08 | 2019-2025 | |
| Lilly USA, LLC | $307.12 | 2019-2024 | Ebglyss, Taltz |
| E.R. Squibb & Sons, L.L.C. | $190.46 | 2023-2024 | Sotyktu |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $175.68 | 2019-2024 | Jublia |
| Arcutis Biotherapeutics, INC. | $161.06 | 2023-2025 | Zoryve |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $151.95 | 2020-2025 | Nemluvio, Aklief |
| Amgen INC. | $129.48 | 2022-2025 | Otezla, Otezla |
| Sanofi-Aventis U.S. LLC | $115.98 | 2021 | |
| Epi Health, LLC | $114.39 | 2019-2021 | |
| Mayne Pharma Commercial LLC | $111.53 | 2020-2025 | |
| Ucb, INC. | $90.96 | 2022-2025 | Bimzelx |
| Almirall LLC | $56.87 | 2019-2025 | Klisyri, Seysara |
| Genentech USA, INC. | $40.20 | 2019-2021 | |
| Botanix Sb INC | $38.83 | 2025 | Sofdra |
| Organon LLC | $33.67 | 2025 | Vtama |
| Krystal Biotech INC | $28.08 | 2023 | Vyjuvek |
| Kyowa Kirin, INC. | $22.96 | 2022 | |
| Celgene Corporation | $18.31 | 2019 | |
| Boston Scientific Corporation | $16.78 | 2022 | |
| Hill Dermaceuticals, INC. | $16.60 | 2025 | Tolak |
| Journey Medical Corporation | $14.98 | 2022 | |
| Encore Dermatology INC. | $14.42 | 2020 | |
| Prugen, INC. Pharmaceuticals | $11.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Owen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.